{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-004295","form_type":"8-K","ticker":"MED","cik":"0000910329","company_name":"MEDIFAST INC","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.507279+00:00","generated_at":"2026-06-19T07:38:26.921923+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Medifast Q4 revenue down 10.7% to $337.2M; guides Q1 revenue $300-320M","bullets":["Q4 GAAP EPS $2.41, adjusted EPS $3.70; net income $26.5M vs $34.0M YoY.","Full-year 2022 revenue up 4.8% to $1.6B; GAAP EPS $12.73, adjusted EPS $14.50.","Active earning OPTA VIA Coaches 60,900 (+1.8% YoY); revenue per coach $5,538 (-12.4%).","Q1 2023 guidance: revenue $300-320M, diluted EPS $1.75-2.40; assumes 26-27% tax rate.","Cash $87.7M, no debt; quarterly dividend of $1.64/share paid Feb 7, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-004295","json":"https://secwatch.observer/filing/0001628280-23-004295.json","markdown":"https://secwatch.observer/filing/0001628280-23-004295.md","text":"https://secwatch.observer/filing/0001628280-23-004295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910329/000162828023004295/0001628280-23-004295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910329/000162828023004295/med-20230221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:38:26.921923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91f742a23451d86d185e04ec0fd269e183def4d1","claim":"MEDIFAST INC reported the fiscal year ended December 31, 2022 results: revenue $1.6 billion, net income $143.6 million, EPS $12.73 per diluted share. Guidance reaffirmed.","evidence_excerpt":"For the fiscal year ended December 31, 2022, revenue increased 4.8% to $1.6 billion compared to revenue of $1.5 billion in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/910329/000162828023004295/0001628280-23-004295-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$1.6 billion"},{"label":"Net income","value":"$143.6 million"},{"label":"EPS","value":"$12.73 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b313fc11e6a27b546a3b7b41e4200ace3de6cdb2","claim":"MEDIFAST INC reported the fourth quarter ended December 31, 2022 results: revenue $337.2 million, net income $26.5 million, EPS $2.41 per diluted share.","evidence_excerpt":"one of the fastest-growing health and wellness communities, OPTA VIA® , today reported results for the fourth quarter ended December 31, 2022. Fourth Quarter 2022 • Revenue of $337.2 million, with revenue per active earning coach of $5,538 • Independent active earning OPTA VIA Coaches of 60,900 • Net income of $26.5 million (non-GAAP adjusted net income of $40.6","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/910329/000162828023004295/0001628280-23-004295-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$337.2 million"},{"label":"Net income","value":"$26.5 million"},{"label":"EPS","value":"$2.41 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}